
INSP Stock Forecast & Price Target
INSP Analyst Ratings
Bulls say
Inspire Medical Systems Inc. has demonstrated a notable increase in spending, with a reported 56% increase in 3Q25, which is anticipated to continue into 4Q25 and throughout 2026, promoting awareness and procedure volumes. The company has reiterated its revenue guidance for 2025 and has raised its full-year GAAP EPS estimate by $0.50 per share following a strong earnings beat in 3Q. Despite a year-to-date decline of 26% in stock price, shares have surged approximately 86% since the Q3 earnings report release, largely driven by favorable updates and improved reimbursement outlooks that are expected to elevate average selling prices (ASPs).
Bears say
Inspire Medical Systems faces a negative outlook primarily due to a slowdown in advertising spending, with projections indicating a 5% year-over-year decrease in 2024 and a further 6% decline in the first half of 2025. The launch of the Inspire 5 product has encountered more challenges than expected, leading management to revise revenue and earnings-per-share forecasts downward, which impacts stock valuation. Additionally, operational expenditures have decreased, reflecting cuts to research and development and selling, general, and administrative costs, indicating potential challenges in sustaining growth and innovation in a competitive market.
This aggregate rating is based on analysts' research of Inspire Medical Systems Inc and is not a guaranteed prediction by Public.com or investment advice.
INSP Analyst Forecast & Price Prediction
Start investing in INSP
Order type
Buy in
Order amount
Est. shares
0 shares